---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product comparison"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product comparison. Topics: Donidalorsen: same target, different oligonucleotide mechanism; Donidalorsen: plasma prekallikrein reduction in OASIS-HAE; Donidalorsen: attack-free rate and dosing frequency as described by the sponsor of onvuzosiran; Donidalorsen: mean attack rate per four weeks in OASIS-HAE; 9 further topics. 13 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/product-comparison"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Donidalorsen: same target, different oligonucleotide mechanism

> “The potential clinical benefit of targeting PKK mRNA is supported by Phase 3 data from donidalorsen, a GalNAc-conjugated ASO that also inhibits PKK mRNA.”
> “Onvuzosiran uses the same biological target as donidalorsen but achieves degradation through a more efficient biological mechanism using the cell’s own natural mRNA regulation system, thereby offering the potential for deeper and more durable PKK suppression.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “Donidalorsen is an ASO-GalNAc conjugate that causes ribonuclease H1 (RNase H1)-mediated degradation of PKK mRNA through binding to PKK mRNA, which results in reduced production of PKK protein.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="topic-2.1.2.14-2"></a>

### Donidalorsen: plasma prekallikrein reduction in OASIS-HAE

> “The mean percentage change from baseline to Week 24 in trough plasma PKK concentrations indicated reductions of 73% and 47% following”
> “treatment with DAWNZERA 80 mg every 4 weeks and every 8 weeks, respectively, compared with a slight increase (2%) observed in the placebo group.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

### Donidalorsen: attack-free rate and dosing frequency as described by the sponsor of onvuzosiran

> “dosing every 4 to 8 weeks remains burdensome for patients and, with an attack-free rate in the Phase 3 study of only 35% (Q8W) to 53% (Q4W), it leaves room for significant improvement in the field.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.14-4"></a>

### Donidalorsen: mean attack rate per four weeks in OASIS-HAE

| Treatment | Attack rate |
| --- | --- |
| Donidalorsen every four weeks | “0.44” |
| Donidalorsen every eight weeks | “1.02” |
| Placebo | “2.26” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="topic-2.1.2.14-5"></a>

### Approved prophylactic agents: limitations described by the sponsor of onvuzosiran

> “These approved prophylactic therapies have provided HAE patients with treatment options but have significant limitations, particularly with respect to efficacy (attack-free rate and reduction in attack frequency), side effects and importantly, frequency of administration.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “Compared to currently approved prophylactic treatments, ADX-324 is expected to decrease PKK to a greater degree, offering the potential for greater and more durable control of kallikrein activity, which is expected to result in a higher proportion of patients remaining attack-free with a less frequent dosing regimen.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-2.1.2.14-6"></a>

### Onvuzosiran target product profile

> “Our target profile for onvuzosiran is to reach greater than 90% reduction in monthly attacks, with greater than 75% of patients achieving attack-free status, on Q3M or Q6M dosing schedule.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.14-7"></a>

### Competing prekallikrein siRNA BW-20805: phase 1 in healthy volunteers

> “BW-20805 is a siRNA that inhibits prekallikrein (PKK), offering the possibility of prevention of Hereditary Angioedema (HAE) attacks with a significant, longer acting effect.”
> “The mean maximum reduction in PKK level from baseline after dosing were 75% (50 mg),87% (150 mg),94% (300 mg), and 95% (600mg).”
> “Those reductions were sustained, remaining greater than 55% (50 mg), 69% (150 mg) and 77% (300 mg) and 84% (600 mg) up to Week 24 post-dose.”
> “The most common study drug-related AEs were mild, transient injection site reactions.”

Source: [Wong et al. (2025)](https://www.annallergy.org/article/S1081-1206%2825%2900537-X/fulltext)

<a id="topic-2.1.2.14-8"></a>

### Competing prekallikrein siRNA BW-20805: phase 2 in participants with HAE

> “As of the June 2026 data cut-off, 25 participants were randomized and dosed across three treatment groups: BW-20805: 600 mg every 24 weeks (Q24W), 300 mg Q24W, and 300 mg every 12 weeks (Q12W).”
> “Mean time-normalized monthly attack rates decreased by 83% in the 600 mg Q24W group, 96% in the 300 mg Q24W group, and 93% in the 300 mg Q12W group”
> “Attack-free rates over Day 29 to 169 were 50% (4/8), 75% (6/8), and 62.5% (5/8) in the 600 mg Q24W, 300 mg Q24W, and 300 mg Q12W groups, respectively.”
> “In the PKK-evaluable population (n=19), mean plasma PKK reductions at Day 169 were 86%, 85%, and 94% in the 600 mg Q24W, 300 mg Q24W, and 300 mg Q12W groups, respectively.”

Source: [Argo Biopharma (2026)](https://www.prnewswire.com/news-releases/argo-biopharma-to-present-positive-phase-ii-updated-results-of-sirna-therapeutic-bw-20805-for-hae-at-bradykinin-symposium-2026-302869556.html)

<a id="topic-2.1.2.14-9"></a>

### Lonvoguran ziclumeran: KLKB1 gene knockout

> “NTLA-2002 is a wholly owned, investigational in vivo CRISPR-based therapy designed to knock out the KLKB1 gene in the liver”

Source: [Intellia Therapeutics (2025)](https://www.sec.gov/Archives/edgar/data/0001652130/000095017025028373/ntla-ex99_1.htm)

| Outcome | NTLA-2002 25 mg | NTLA-2002 50 mg | Placebo |
| --- | --- | --- | --- |
| Plasma kallikrein change from baseline, week 16 | “-55%” | “-86%” | “2%” |

Source: [Intellia Therapeutics investor presentation (2024)](https://www.intelliatx.com/wp-content/uploads/Intellia_NTLA-2002-Phase-2-Data-Investor-Presentation_10.24.24_vF.pdf)

<a id="topic-2.1.2.14-10"></a>

### Network meta-analysis of approved prophylactic agents: time-normalized attack rate

> “Additional relative effect estimates showed a statistically significant reduction in the rate of attacks for garadacimab compared with every treatment other than lanadelumab 300 Q2W (Fig. 8).”
> “Lanadelumab 300 Q2W showed statistically significant reductions compared with lanadelumab 300 Q4W, berotralstat, and placebo (Fig. 8).”

Source: [Walsh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/)

| Treatment | Probability of being best (%) | SUCRA (%) |
| --- | --- | --- |
| Garadacimab 200 mg once monthly | “73” | “94” |
| Lanadelumab 300 mg every 2 weeks | “26” | “83” |
| Subcutaneous C1INH 60 IU/kg twice weekly | “1” | “62” |
| Lanadelumab 300 mg every 4 weeks | “0” | “40” |
| Berotralstat 150 mg once daily | “0” | “20” |

Source: [Walsh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/)

<a id="topic-2.1.2.14-11"></a>

### Network meta-analysis of approved prophylactic agents: attack-free participants

> “The fixed-effect model showed that four active treatments, garadacimab, lanadelumab 300 Q2W, lanadelumab 300 Q4W, and subcutaneous C1INH, statistically significantly increased the proportion of attack-free patients compared with placebo (Fig. 9).”
> “Additional relative effect estimates between the active treatments did not demonstrate statistically significant results (Fig. 10).”

Source: [Walsh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/)

<a id="topic-2.1.2.14-12"></a>

### Network meta-analysis of lanadelumab and berotralstat: attack rate per 28 days

> “In this NMA, lanadelumab 300 mg administered every 2 weeks or every 4 weeks was associated with statistically significantly higher effectiveness versus berotralstat 150 mg once daily (q.d.) or 110 mg q.d. for both efficacy outcomes assessed.”

Source: [Watt et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10402909/)

| Comparison | Rate ratio (95% CI); p-value |
| --- | --- |
| Lanadelumab 300 mg every 2 weeks vs berotralstat 150 mg once daily | “0.23 (0.10, 0.55); p = 0.0009” |
| Lanadelumab 300 mg every 2 weeks vs C1-INH 1000 IU twice weekly | “0.27 (0.11, 0.64); p = 0.0032” |
| Lanadelumab 300 mg every 2 weeks vs placebo | “0.13 (0.06, 0.29); p < 0.0001” |
| Lanadelumab 300 mg every 4 weeks vs berotralstat 150 mg once daily | “0.48 (0.25, 0.94); p = 0.0311” |
| Lanadelumab 300 mg every 4 weeks vs placebo | “0.27 (0.15, 0.47); p < 0.0001” |

Source: [Watt et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10402909/)

<a id="topic-2.1.2.14-13"></a>

### Cross-trial comparison limitations

> “There are risks inherent in conducting cross-study comparisons and the results should be interpreted with caution.”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

> “Following the assessment of NMA feasibility, residual heterogeneity between trials may have persisted, despite our best efforts to minimize bias by excluding insufficiently similar trials and/or trial data.”
> “All trials were placebo controlled, rather than head-to-head, which further simplified network structures.”
> “These network characteristics increase the potential for biased treatment effect estimates, which limits the robustness of the analysis.”

Source: [Walsh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/)

> “NMAs cannot be a substitute for head-to-head comparisons”

Source: [Watt et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10402909/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
